Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EGRX / TEVA good news
taking some uvxy lottos and tza calls into next week
UVXY 14c .37
TZA 38.5c
This weeks 11c .34 will hold into close
sold last weekly 10c at 1.15 from .39 entry
taking some uvxy lottos and tza calls into next week
UVXY 14c .37
TZA 38.5c
This weeks 11c .34 will hold into close
sold last weekly 10c at 1.15 from .39 entry
Any views on ICPT if suitable for a bigger suitor in this current stage ?
rolled out UVXY 10c into 11ct at .35 , 7ct stop .. locking gains/. UVXY 10c entry .39.. sold 1.15 remainder
rolled out UVXY 10c into 11ct at .35 , 7ct stop .. locking gains/. UVXY 10c entry .39.. sold 1.15 remainder
sold halve UVXY 10c at 1.19 from .39
sold halve UVXY 10c at 1.19 from .39
Consumer poll shows that Chipotle no longer the preferred brand
http://www.fool.com/investing/2016/06/09/2-reasons-chipotles-stock-tanked-in-thursday.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2&yptr=yahoo
added UVXY 11c , raised stop on 10c
uvxy 10c .38 cost avg now
CMG 460c out 2.1 from .6
BIDU 165p out .49 from .24
small though
TSLA 227.5p .38
TSLA 227.5p .38
rolled tza 35.5 to 35
TZA 35.5 with stop
tsla 240c out .69 and .82 from .18
BIDU 180c , NFLX target 104
Valeant Pharma sees FY2016 EPS of $6.60-$7.00, versus prior guidance of $8.50-$9.50 and the consensus of $8.47. Valeant Pharma sees FY2016 revenue of $9.9-10.1 billion, versus prior guidance of $11.0-11.2 billion and the consensus of $10.86 billion.
it dropped from 125$ to 28$ in the months prior to releasing these numbers from ealrier highs of 250$
Valeant Pharma sees FY2016 EPS of $6.60-$7.00, versus prior guidance of $8.50-$9.50 and the consensus of $8.47. Valeant Pharma sees FY2016 revenue of $9.9-10.1 billion, versus prior guidance of $11.0-11.2 billion and the consensus of $10.86 billion.
it dropped from 125$ to 28$ in the months prior to releasing these numbers from ealrier highs of 250$
CMG daily chart
CMG daily chart
NFLX 104c .31 CMG 460c .55 VRX 35c .37 SCTY june 17th 23c .7
NFLX 104c .31 CMG 460c .55 VRX 35c .37 SCTY june 17th 23c .7
VRX 35c .36 high risk, delayed earnings release expected tuesday
CMG price to earnings at 42 , no recovery prior to 2018 expected and now also insider sales as well as fidelity selling
CMG price to earnings at 42 , no recovery prior to 2018 expected and now also insider sales as well as fidelity selling
AMZN ready
our few XLE 66.5p at .65 from .24
CMG 460c .75
SODA 21.5c .2
AMZN 745c .35
WYNN june 17th 105c .47
csco 29p .17 uvxy 12c .20
csco 29p .17 uvxy 12c .20
SHLD 13.5c sold halve .90 and halve .49 avg preset sales from .20 avg
SHLD 13.5c sold halve .90 and halve .49 avg preset sales from .20 avg
good odds on SHLD .. took 13.5c .2 last week for may 27th .. earnings tomorrow
TSLA still looks like quick flush under 200 likely
long VRX , 30c .41 31.5c .27
out HD 132p 1.05 from 1.20 entry
nice salvage, should have rocketed higher on these numbers
few NVDA 41p .35